comms@paragonbiosci.com

58 items

September 1, 2020

Emalex Biosciences Phase 2b Tourette Syndrome Clinical Trial Reaches Enrollment Milestone
– Half of participants are now enrolled [...]
August 21, 2020

Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
PLYMOUTH MEETING, PA and CHICAGO, IL, August 21, [...]
August 19, 2020

Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering
PLYMOUTH MEETING, PA and CHICAGO, IL, August 18, [...]
August 12, 2020

Paragon Biosciences Appoints Kerensa Jimenez as Paragon Health Capital Chief Executive Officer
Chicago, August 12, 2020 – With strong momentum [...]
August 6, 2020

Sterling Bay Signs Lease with Evozyne, LLC at Lincoln Park Life Science Building, 2430 N Halsted
Sterling Bay Signs Lease with Evozyne, LLC [...]
July 23, 2020

Synthetic Protein Design and Production Publication Confirms Evozyne’s Revolutionary Technology
Publication in peer-reviewed journal Science demonstrates the foundation [...]
June 3, 2020

Horizon Technology Finance and Emalex Biosciences Announce $15 Million Venture Loan Facility
– Biopharmaceutical company advancing clinical research evaluating novel [...]
May 19, 2020

Philadelphia Magazine features a Paragon portfolio company as a leader in cell and gene therapy innovation
May 19, 2020 – We are proud to share [...]

Previous 456 Next